Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways is preparing for the commercial launch of COMP360, its psilocybin-based therapy for treatment-resistant depression, with an FDA submission expected to complete in late 2026. To succeed, Compass is leveraging the clinical infrastructure established by Johnson & Johnson's Spravato, which expanded the U.S. network of interventional psychiatry clinics to 8,500. Compass has grown its commercial team to 100 employees and established a multi-hour reimbursement framework to support clinics.

COMP360 regulatory submission timeline

• ▪Jefferies analysts estimate a 75% to 85% chance of FDA approval for COMP360 in 2026, with a potential market launch by the first half of 2027.
• ▪Compass Pathways is conducting a rolling submission to the FDA for COMP360, its psilocybin-based candidate for treatment-resistant depression.
• ▪COMP360 succeeded in two Phase 3 clinical trials for treatment-resistant depression, demonstrating durability and clinical efficacy.
• ▪Compass Pathways expects to complete its FDA rolling submission for COMP360 in the fourth quarter of 2026.

Spravato infrastructure precedent

• ▪Johnson & Johnson's Spravato, an inhaled esketamine treatment approved in 2019, established the clinical infrastructure that Compass Pathways plans to utilize for COMP360.
• ▪Johnson & Johnson's Spravato generated more than $1 billion in revenue during the first half of 2026.

Interventional psychiatry clinic capacity

• ▪The number of interventional psychiatry clinics in the United States grew from a small handful in 2019 to approximately 8,500 clinics in 2026.
• ▪COMP360 is designed to slot directly into existing clinic workflows, utilizing the same multidisciplinary staff that currently monitors Spravato patients.
• ▪Interventional psychiatry clinics have built excess capacity ahead of new drug approvals, partly because Spravato requires 25 to 50 three-hour visits per year.

Psychedelic therapy competitive landscape

• ▪Compass Pathways CEO Kabir Nath states that COMP360 will target the estimated 4 million treatment-resistant depression patients who are not currently taking Spravato.
• ▪Definium Therapeutics is developing DT120, an LSD-based formulation that has succeeded in Phase 3 trials for major depressive disorder and generalized anxiety disorder.
• ▪Eli Lilly acquired AtaiBeckley for $3.8 billion in the summer of 2026, representing a major pharmaceutical acquisition in the psychedelic therapeutics sector.
• ▪AbbVie acquired Gilgamesh Pharmaceuticals' depression drug bretisilocin for $1.2 billion, while Otsuka Pharmaceutical acquired Mindset Pharma in 2023.

Commercial launch strategy

• ▪Compass Pathways will wait to hire its final field-facing commercial teams until after receiving FDA approval for COMP360.
• ▪Compass Pathways expanded its commercial team from 20 employees at the beginning of 2026 to approximately 100 employees by September 2026.
• ▪Compass Pathways plans a highly contained, carefully managed initial launch for COMP360 to ensure positive early patient experiences before scaling.

Reimbursement framework for clinics

• ▪Compass Pathways established a reimbursement framework to ensure clinics are reimbursed for every hour of the six-to-eight-hour COMP360 observation period.
• ▪Compass Pathways expects the hourly reimbursement rate for COMP360 administration to be higher than the rate currently paid for Spravato.